Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472264 · ClinicalTrials.gov registry record
A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 20
- Enrollment target
NCT00472264: Clinical Trial study, sponsored by Pfizer.
NCT00472264 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00472264 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 20 participants
- Enrollment target
Study Summary
It is hypothesised that there is a difference between the uptake of a radioactive substance (\[18F\]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.
Interventions
- PROCEDURE PET imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-05 |
| Est. Completion | 2008-11 |
Why NCT00472264 stopped before completion
NCT00472264 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PET imaging is the first listed.
NCT00472264 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00472264 about?
NCT00472264 is a clinical study titled "A Study To Investigate The Ability To Use 18FDG PET Scanning To Monitor The Effectiveness Of New Drugs In COPD Patients". It is hypothesised that there is a difference between the uptake of a radioactive substance (\[18F\]fluorodeoxyglucose (FDG)) in the lungs of patients with Chronic Obstructive Pulmonary Disease (COPD) and healthy volunteers.
What is the current status of trial NCT00472264?
This trial is currently terminated. The enrollment target is 20 participants. The study started on 2007-05. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00472264?
The interventions under investigation include: PET imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00472264?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia